Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Biotek-snakken
  4. Biotek-snakken — April 2024

Biotek-snakken — April 2024

Planlagt Fastgjort Låst Flyttet Biotek-snakken
112 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • L Offline
    L Offline
    LP90
    wrote on sidst redigeret af
    #47

    Godmorgen 🙂

    1 Reply Last reply
    0
    • P Offline
      P Offline
      ProinvestorNEWS
      wrote on sidst redigeret af
      #48

      ULTIMOVACS: Biotekselskapet melder at de vil redusere antall ansatte med 40% slik at de skal ha likviditet til å nå ytterligere to datapunkter - pengene skal etter plan holde til Q4 2025.

      1 Reply Last reply
      0
      • F Offline
        F Offline
        Fandel
        wrote on sidst redigeret af
        #49

        Godmorgen...

        1 Reply Last reply
        0
        • L Offline
          L Offline
          LP90
          wrote on sidst redigeret af
          #50

          Godmorgen 🙂

          1 Reply Last reply
          0
          • exitnuE Offline
            exitnuE Offline
            exitnu
            wrote on sidst redigeret af
            #51

            Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024

            Link Preview Image
            Calliditas Therapeutics AB

            Calliditas is a commercial stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

            favicon

            Calliditas Therapeutics AB (www.calliditas.se)

            1 Reply Last reply
            0
            • F Offline
              F Offline
              Fandel
              wrote on sidst redigeret af
              #52

              Godmorgen...

              1 Reply Last reply
              0
              • L Offline
                L Offline
                LP90
                wrote on sidst redigeret af
                #53

                Godmorgen 🙂

                1 Reply Last reply
                0
                • F Offline
                  F Offline
                  Fandel
                  wrote on sidst redigeret af
                  #54

                  Godmorgen...

                  1 Reply Last reply
                  0
                  • F Offline
                    F Offline
                    Fandel
                    wrote on sidst redigeret af
                    #55

                    Godmorgen...

                    1 Reply Last reply
                    0
                    • Helge_LarsenPI-redaktørH Offline
                      Helge_LarsenPI-redaktørH Offline
                      Helge_LarsenPI-redaktør
                      wrote on sidst redigeret af
                      #56

                      BioArctic And Eisai Collaborate On Evaluating BAN2802 For Alzheimer's Disease https://www.proinvestor.com/investornyt/1148131/bioarctic-and-eisai-collaborate-on-evaluating-ban2802-for-alzheimers-disease

                      1 Reply Last reply
                      0
                      • H Offline
                        H Offline
                        Hansen
                        wrote on sidst redigeret af
                        #57

                        Xbane lidt nyt https://xbrane.com/mfn_news/xbrane-uppdaterar-kring-fdas-granskning-av-ranibizumab-biosimilarkandidat/

                        1 Reply Last reply
                        0
                        • H Offline
                          H Offline
                          Hansen
                          wrote on sidst redigeret af
                          #58

                          Xbrane 🙂

                          1 Reply Last reply
                          0
                          • F Offline
                            F Offline
                            Fandel
                            wrote on sidst redigeret af
                            #59

                            Godmorgen...

                            1 Reply Last reply
                            0
                            • L Offline
                              L Offline
                              LP90
                              wrote on sidst redigeret af
                              #60

                              Godmorgen 🙂

                              1 Reply Last reply
                              0
                              • exitnuE Offline
                                exitnuE Offline
                                exitnu
                                wrote on sidst redigeret af
                                #61

                                God morgen 🙂

                                1 Reply Last reply
                                0
                                • exitnuE Offline
                                  exitnuE Offline
                                  exitnu
                                  wrote on sidst redigeret af
                                  #62

                                  En fabriksorienteret Complete Response Letter (CRL) kan typisk resultere i en forlængelse på 1 til 6 måneder, men i visse tilfælde kan forlængelsen vare op til 12 måneder eller mere.

                                  "Receiving a complete response letter is not a rejection, but it introduces important business questions for product launch planning."

                                  https://avalere.com/insights/what-is-a-complete-response-letter

                                  (Avalere)

                                  1 Reply Last reply
                                  0
                                  • H Offline
                                    H Offline
                                    Hansen
                                    wrote on sidst redigeret af
                                    #63

                                    På den positive side, lyder det som om at det er overkommeligt at efterkomme. Ikke mindst at der ikke kræves flere forsøg. Eller er det for optimistisk at se på det sådan?

                                    1 Reply Last reply
                                    0
                                    • exitnuE Offline
                                      exitnuE Offline
                                      exitnu
                                      wrote on sidst redigeret af
                                      #64

                                      Complete Response Letter (CRL) betyder en udfordring for Xbrane. De skal håndtere forsinkelsen, ekstra omkostninger men også en ekstra usikkerhed omkring godkendelse. Rent statistisk er høj godkendelsesraten for biosimilar ganske pæn. Har ikke Xbrane.

                                      1 Reply Last reply
                                      0
                                      • exitnuE Offline
                                        exitnuE Offline
                                        exitnu
                                        wrote on sidst redigeret af
                                        #65

                                        ... er godkendelsesraten høj ...

                                        1 Reply Last reply
                                        0
                                        • exitnuE Offline
                                          exitnuE Offline
                                          exitnu
                                          wrote on sidst redigeret af
                                          #66

                                          Xbrane Biopharma: Ximluci – CRL

                                          Redeye provides its initial comments on yesterday evening’s news that Xbrane has received a CRL from the FDA related to its Ximluci BLA. This means the FDA requires additional clarifications and a potential US approval will be delayed.

                                          Just a moment...

                                          favicon

                                          (www.redeye.se)

                                          (Redeye)

                                          "Given the available information, we believe that a realistic expectation for a new BsUFA date would be in the coming 6-9 months."

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper